149 related articles for article (PubMed ID: 34716509)
21. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
[TBL] [Abstract][Full Text] [Related]
22. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
Rothschild HT; Clelland E; Patterson A; Molina-Vega J; Kaur M; Symmans WF; Schwartz CJ; Chien AJ; Mukhtar RA
Breast Cancer Res Treat; 2023 Jun; 199(2):349-354. PubMed ID: 37017812
[TBL] [Abstract][Full Text] [Related]
23. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
[TBL] [Abstract][Full Text] [Related]
25. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
Van Baelen K; Geukens T; Maetens M; Tjan-Heijnen V; Lord CJ; Linn S; Bidard FC; Richard F; Yang WW; Steele RE; Pettitt SJ; Van Ongeval C; De Schepper M; Isnaldi E; Nevelsteen I; Smeets A; Punie K; Voorwerk L; Wildiers H; Floris G; Vincent-Salomon A; Derksen PWB; Neven P; Senkus E; Sawyer E; Kok M; Desmedt C
Ann Oncol; 2022 Aug; 33(8):769-785. PubMed ID: 35605746
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.
de Nonneville A; Jauffret C; Gonçalves A; Classe JM; Cohen M; Reyal F; Mazouni C; Chauvet MP; Chopin N; Colombo PE; Jouve E; Darai E; Rouzier R; Coutant C; Gimbergues P; Azuar AS; de Lara CT; Lambaudie E; Houvenaeghel G
Breast Cancer Res Treat; 2019 Jun; 175(2):379-387. PubMed ID: 30759288
[TBL] [Abstract][Full Text] [Related]
27. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
[TBL] [Abstract][Full Text] [Related]
28. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
31. Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes.
Yaghi M; Bilani N; Dominguez B; Jabbal IS; Rivera C; Bou Zerdan M; Li H; Saravia D; Stone E; Nahleh Z
Breast; 2022 Aug; 64():112-120. PubMed ID: 35640346
[TBL] [Abstract][Full Text] [Related]
32. 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer.
Chen XH; Zhang WW; Wang J; Sun JY; Li FY; He ZY; Wu SG
Biomark Med; 2019 Feb; 13(2):83-93. PubMed ID: 30565472
[TBL] [Abstract][Full Text] [Related]
33. The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution.
Watanabe J; Nakamoto S; Sugino T
Anticancer Res; 2021 Sep; 41(9):4619-4627. PubMed ID: 34475090
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.
Pramod N; Nigam A; Basree M; Mawalkar R; Mehra S; Shinde N; Tozbikian G; Williams N; Majumder S; Ramaswamy B
Oncologist; 2021 Jun; 26(6):e943-e953. PubMed ID: 33641217
[TBL] [Abstract][Full Text] [Related]
35. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes.
Engstrøm MJ; Opdahl S; Vatten LJ; Haugen OA; Bofin AM
Histopathology; 2015 Feb; 66(3):409-19. PubMed ID: 25283075
[TBL] [Abstract][Full Text] [Related]
36. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
Rakha EA; El-Sayed ME; Powe DG; Green AR; Habashy H; Grainge MJ; Robertson JF; Blamey R; Gee J; Nicholson RI; Lee AH; Ellis IO
Eur J Cancer; 2008 Jan; 44(1):73-83. PubMed ID: 18035533
[TBL] [Abstract][Full Text] [Related]
37. Impact of neoadjuvant and adjuvant chemotherapy on invasive lobular carcinoma: A propensity score-matched analysis of SEER data.
Watanuki R; Hayashida T; Yokoe T; Kawai Y; Kikuchi M; Nakashoji A; Nagayama A; Seki T; Takahashi M; Kitagawa Y
Breast J; 2020 Sep; 26(9):1765-1770. PubMed ID: 32449173
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
40. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
Felts JL; Zhu J; Han B; Smith SJ; Truica CI
Breast J; 2017 Nov; 23(6):677-686. PubMed ID: 28097781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]